PD153035 HCl

Catalog No.S1079 Batch:S107901

Print

Technical Data

Formula

C16H14BrN3O2.HCl
Molecular Weight 396.67 CAS No. 183322-45-4
Solubility (25°C)* In vitro 4-Methylpyridine (warmed with 50ºC water bath) 5 mg/mL (12.6 mM)
DMSO 0.5 mg/mL (1.26 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
30%propylene glycol 5%Tween80 65%D5W
30.0mg/ml Taking the 1 mL working solution as an example, add 300 μL of 100 mg/ml clarified propylene glycol stock solution to 50 μL of Tween 80, mix evenly to clarify it; then continue to add 650 μL of D5W to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description PD153035 HCl (SU-5271 HCl, AG1517 HCl, ZM 252868 HCl) is a potent and specific inhibitor of EGFR with Ki and IC50 of 5.2 pM and 29 pM in cell-free assays; little effect noted against PGDFR, FGFR, CSF-1, InsR and Src.
Targets
EGFR [1]
(Cell-free assay)
5.2 pM(Ki)
In vitro PD 153035 shows a potent and selective inhibitory effect on tyrosine phosphorylation induced with EGF with IC50 of 15 nM and 14 nM in Swiss 3T3 fibroblast and A-431 human epidermoid carcinoma cells, respectively. [1] PD153035 shows growth inhibitory effects in cultures of EGF receptor-overexpressing human cancer cell lines including A431, Difi, DU145, MDA-MB-468 and ME180 cells with IC50 of 0.22 μM, 0.3μM, 0.4 μM, 0.68 μM and 0.95 μM, respectively. [2] PD153035 induces a dose-dependent growth inhibition in nasopharyngeal carcinoma (NPC) cells including NPC-TW01, NPC-TW04, and HONE1 cell lines with IC50 of 12.9 μM, 9.8 μM and 18.6μM, respectively. [3] A recent study shows that PD153035 abolishes COX-2 expression induced by the PAR(2)-activating peptide 2-furoyl-LIGRLO-NH(2) (2fLI) in Caco-2 colon cancer cells. [4]
In vivo In A431 human epidermoid tumors grown as xenografts in immunodeficient nude mice, PD153035 at 80 mg/kg inhibit EGF receptor tyrosine kinase activity. [5] PD153035 improves glucose tolerance, insulin sensitivity, and signaling and reduces subclinical inflammation in HFD-fed mice. [6] Pretreatment of EGFR inhibitors by 24 hours significantly enhances the cytotoxic effect of doxorubicin, paclitaxel, cisplatin, and 5-fluororuacil in NPCTW04 cells. [3]

Protocol (from reference)

Kinase Assay:[1]
  • Inhibition of EGF receptor tyrosine kinase

    Enzyme reactions are performed in a total volume of 0.1 mL containing 25 mM Hepes (pH 7.4), 5 mM MgCl2, 2 mM MnCl2, 50 μM sodium vanadate, 0.5 to 1.0 ng of enzyme (which also contains enough EGF to make the final concentrations 2 μg/mL), 10 μM ATP containing 1 μCi of [32P]ATP, varying concentrations of PD153035, and 200 μM of a substrate peptide based on a portion of phospholipase C-γl having the sequence Lys-His-Lys-Lys-Leu-Ala-Glu-Gly-Ser-Ala-Tyr472-Glu-Glu-Val. The reaction is initiated by the addition of ATP. After 10 minutes at room temperature, the reaction is terminated by addition of 2 mL of 75 mM phosphoric acid, and the solution is passed through a 2.5-cm phosphocellulose filter disk that binds the peptide. The filter is washed five times with 75 mM phosphoric acid and placed in a vial with 5 mL of scintillation fluid. The uninhibited control activity produces approximately 100,000 cpm.
Cell Assay:[2]
  • Cell lines

    A431, Difi, DU145, MDA-MB-468 and ME180

  • Concentrations

    0-3 μM

  • Incubation Time

    72 hours

  • Method

    Cells are seeded in sixwell plates. The next day, cells are changed to medium containing 0.5% FBS for 18 hours, and then PD153035 is added at various concentrations to the cultures. After 72 hours of treatment, cells are washed once with PBS, harvested with 0.1% human trypsin-l mM EDTA in PBS, and counted with a Coulter counter. The CMK cells grow in suspension and, therefore, do not require trypsinization.
Animal Study:[5]
  • Animal Models

    A431 cells are injected into the outbred nude mice.

  • Dosages

    ≤80 mg/kg

  • Administration

    Administered via i.p.

Customer Product Validation

Data from [J Immunol, 2012, 188(9), 4581-4589 ]

, 2010, Dr. Zhang of Tianjin Medical University

Data from [Data independently produced by , , Oncotarget, 2016, 7(24):36168-36184.]

Selleck's PD153035 HCl has been cited by 18 publications

Receptor-kinase EGFR-MAPK adaptor proteins mediate the epithelial response to Candida albicans via the cytolytic peptide toxin, candidalysin [ J Biol Chem, 2022, 298(10):102419] PubMed: 36037968
Hemodynamic Forces Regulate Cardiac Regeneration-Responsive Enhancer Activity during Ventricle Regeneration [ Int J Mol Sci, 2021, 22(8)3945] PubMed: 33920448
Identification of chemical compounds regulating PD-L1 by introducing HiBiT-tagged cells [ FEBS Lett, 2021, 595(5):563-576] PubMed: 33421110
Identification of chemical compounds regulating PD-L1 by introducing HiBiT-tagged cells [ FEBS Lett, 2021, 10.1002/1873-3468.14032] PubMed: 33421110
RAB31 marks and controls an ESCRT-independent exosome pathway [ Cell Res, 2020, 10.1038/s41422-020-00409-1] PubMed: 32958903
CD147 promotes collective invasion through cathepsin B in hepatocellular carcinoma [ J Exp Clin Cancer Res, 2020, 39(1):145] PubMed: 32727598
AREG mediates the epithelial‑mesenchymal transition in pancreatic cancer cells via the EGFR/ERK/NF‑κB signalling pathway. [ Oncol Rep, 2020, 43(5):1558-1568] PubMed: 32323797
Epidermal growth factor receptor inhibition attenuates non-alcoholic fatty liver disease in diet-induced obese mice [ PLoS One, 2019, 14(2):e0210828] PubMed: 30735525
Intelectin contributes to allergen-induced IL-25, IL-33, and TSLP expression and type 2 response in asthma and atopic dermatitis. [ Mucosal Immunol, 2017, 10(6):1491-1503] PubMed: 28224996
[ Oncotarget, 2016, ] PubMed: 27556697

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.